Clinical trials
PD-L1 clinical trials
Below are recruiting pd-l1 clinical trials, each written for real people, not researchers. We’re tracking 106 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07026474RecruitingPhase 3
Re-radiation plus immunotherapy for recurrent head and neck cancer
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
BerlinAges 18 years+ - NCT07014137RecruitingPhase 2
A study of an oral pill for angiogenic sarcomas
This trial tests an oral medication (ABSK043) that may help your immune system fight certain rare sarcomas. It is for people with intimal sarcoma, head and neck angiosarcoma, or epithelioid hemangioendothelioma that has spread or cannot be removed by surgery.
Toronto, OntarioAges 18 years+ - NCT07020065RecruitingPhase 2
Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Fribourg, Villars-sur-GlâneAges 70 years+ - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06771609RecruitingPhase 2
Immunotherapy plus low-dose chemo for advanced triple-negative breast cancer
This study tests a combination of an immunotherapy drug (PD-L1 inhibitor) with a special low-dose chemotherapy regimen (VEX) plus optional radiation for advanced triple-negative breast cancer. The goal is to see if this approach works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06758401RecruitingPhase 3
Study of combination treatment for advanced lung cancer with high PD-L1
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
Fullerton, CaliforniaAges 18 years+ - NCT06662006RecruitingPhase 2
Nal-IRI chemo with immunotherapy and radiation for pancreatic cancer
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Nanjing, JiangsuAges 18–75 - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06492759RecruitingPhase 2
High-dose radiation with pembrolizumab and chemo for pd-l1 positive tnbc
This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.
Atlanta, GeorgiaAges 18 years+ - NCT06253611RecruitingPhase 2
Probiotic plus immunotherapy and chemo for stomach cancer
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
AngersAges 18 years+ - NCT06345729RecruitingPhase 3
Combination drug therapy for advanced lung cancer
This trial tests a new pill (calderasib) combined with an immunotherapy drug (pembrolizumab) for people with a specific type of advanced non-small cell lung cancer. It aims to see if the combination can shrink tumors or slow their growth.
Bakersfield, CaliforniaAges 18 years+ - NCT06357533RecruitingPhase 3
New drug combo for advanced lung cancer with high PD-L1
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
Anchorage, AlaskaAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80 - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Phoenix, ArizonaAges 18 years+ - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+ - NCT06012734RecruitingPhase 1
LB-100 plus Atezolizumab for metastatic colorectal cancer
This trial tests a new two-drug combination (LB-100 plus atezolizumab) for people with metastatic colorectal cancer that hasn't responded to standard treatment. The goal is to see if the combination can help shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT05765084RecruitingPhase 1/Phase 2
Atezolizumab plus WT1 vaccine with chemo for pleural mesothelioma
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
Edegem, AntwerpAges 18 years+ - NCT05669846RecruitingPhase 2
FMT plus pembrolizumab for advanced lung cancer after prior treatment
This Phase 2 trial studies whether adding fecal microbiome transplant (FMT) to pembrolizumab can help people with advanced, PD-L1–positive non-small cell lung cancer that has returned or progressed after anti–PD-1/PD-L1 therapy. You may be asked to give new tumor tissue and undergo gut procedures, because the study aims to change gut bacteria to boost the immune response.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05477927RecruitingPhase 1
CAR-T therapy for cancers spread to lining of lungs, belly, or brain
This trial tests an experimental CAR-T cell treatment that targets proteins on cancer cells that have spread to the lining of the lungs, belly, or brain. It may help people whose cancer has not responded to standard treatments.
Chengdu, SichuanAges 18–80 - NCT05142189RecruitingPhase 1
Testing BNT116 for advanced non-small cell lung cancer
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Lexington, KentuckyAges 18 years+ - NCT04806412Recruiting
Gene testing in lung cancer fluid samples
This study looks at fluid from around the lungs (pleural fluid) to find gene changes (oncodrivers) in people with non-small cell lung cancer. The goal is to see if this fluid can replace a tissue biopsy for testing.
Næstved, Region SjællandAges 18 years+
Hear when a new PD-L1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pd-l1?
- Yes. Clin2 currently lists 106 recruiting pd-l1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pd-l1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pd-l1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.